KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Non-Current Deferred Tax Liability: 2010-2025

Historic Non-Current Deferred Tax Liability for Charles River Laboratories International (CRL) over the last 10 years, with Sep 2025 value amounting to $123.0 million.

  • Charles River Laboratories International's Non-Current Deferred Tax Liability fell 26.67% to $123.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.0 million, marking a year-over-year decrease of 26.67%. This contributed to the annual value of $107.0 million for FY2024, which is 75.77% down from last year.
  • Charles River Laboratories International's Non-Current Deferred Tax Liability amounted to $123.0 million in Q3 2025, which was up 12.57% from $109.3 million recorded in Q2 2025.
  • Charles River Laboratories International's 5-year Non-Current Deferred Tax Liability high stood at $441.4 million for Q4 2023, and its period low was $107.0 million during Q4 2024.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $167.7 million (2024), whereas its average is $182.4 million.
  • Per our database at Business Quant, Charles River Laboratories International's Non-Current Deferred Tax Liability soared by 30.12% in 2021 and then tumbled by 75.77% in 2024.
  • Charles River Laboratories International's Non-Current Deferred Tax Liability (Quarterly) stood at $420.6 million in 2021, then grew by 2.97% to $433.1 million in 2022, then climbed by 1.92% to $441.4 million in 2023, then plummeted by 75.77% to $107.0 million in 2024, then dropped by 26.67% to $123.0 million in 2025.
  • Its Non-Current Deferred Tax Liability was $123.0 million in Q3 2025, compared to $109.3 million in Q2 2025 and $107.3 million in Q1 2025.